EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The protein deacetylase SIRT2 exerts metabolic control over adaptive β cell proliferation

Matthew Wortham, Bastian Ramms, Chun Zeng, Jacqueline R Benthuysen, Somesh Sai, Dennis P Pollow, Fenfen Liu, Michael Schlichting, Austin R Harrington, Bradley Liu, Thazha P Prakash, Elaine C Pirie und 8 weitere

Journal of Clinical Investigation · 01.10.2025 · 135 (19)

DOI: 10.1172/jci187020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 31.07.2025. Verfasst von Matthew Wortham und 19 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pediatrics and Cellular and Molecular Medicine, Pediatric Diabetes Research Center, UCSD, La Jolla, California, USA. Hauptthemen laut MEDLINE: Sirtuin 2, Insulin-Secreting Cells, Cell Proliferation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selective and controlled expansion of endogenous β cells has been pursued as a potential therapy for diabetes. Ideally, such therapies would preserve feedback control of β cell proliferation to avoid excessive β cell expansion. Here, we identified a regulator of β cell proliferation whose inactivation resulted in controlled β cell expansion: the protein deacetylase sirtuin 2 (SIRT2). Sirt2 deletion in β cells of mice increased β cell proliferation during hyperglycemia with little effect under homeostatic conditions, indicating preservation of feedback control of β cell mass. SIRT2 restrains proliferation of human islet β cells, demonstrating conserved SIRT2 function. Analysis of acetylated proteins in islets treated with a SIRT2 inhibitor revealed that SIRT2 deacetylates enzymes involved in oxidative phosphorylation, dampening the adaptive increase in oxygen consumption during hyperglycemia. At the transcriptomic level, Sirt2 inactivation has context-dependent effects on β cells, with Sirt2 controlling how β cells interpret hyperglycemia as a stress. Finally, we provide proof of principle that systemic administration of a glucagon-like peptide 1–coupled (GLP1-coupled), Sirt2 -targeting antisense oligonucleotide achieves β cell Sirt2 inactivation and stimulates β cell proliferation during hyperglycemia. Overall, these studies identify a therapeutic strategy for increasing β cell mass in diabetes without circumventing feedback control of β cell proliferation. Future work should test the extent to which these findings translate to human β cells from individuals with or without diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sirtuin 2Insulin-Secreting CellsCell ProliferationAnimalsMiceHumansHyperglycemiaMice, KnockoutMale

Stichwörter der Autor:innen

Beta cellsDiabetesEndocrinologyMetabolismMitochondria

Substanzen

Sirtuin 2Sirt2 protein, mouseSIRT2 protein, human

Autor:innen und Institutionen

  • Departments of Pediatrics and Cellular and Molecular Medicine, Pediatric Diabetes Research Center, UCSD, La Jolla, California, USA.
  • Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Institute of Chemistry and Biochemistry, Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Berlin, Germany.
  • Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • Department of Antisense Drug Discovery, Ionis Pharmaceuticals Inc., Carlsbad, California, USA.
  • Departments of Medicine and Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health
  • Juvenile Diabetes Research Foundation International
  • Larry L. Hillblom Foundation
  • European Research Council
  • Swiss National Science Foundation

Zitieren

APA

Wortham, M., Ramms, B., Zeng, C., Benthuysen, J. R., Sai, S., Pollow, D. P., Liu, F., Schlichting, M., Harrington, A. R., Liu, B., Prakash, T. P., Pirie, E. C., Zhu, H., Baghdasarian, S., Lee, S. T., Ruthig, V. A., Wells, K. L., Auwerx, J., Shirihai, O. S., & Sander, M. (2025). The protein deacetylase SIRT2 exerts metabolic control over adaptive β cell proliferation. Journal of Clinical Investigation, 135(19). https://doi.org/10.1172/jci187020

Vancouver

Wortham M, Ramms B, Zeng C, Benthuysen JR, Sai S, Pollow DP, et al. The protein deacetylase SIRT2 exerts metabolic control over adaptive β cell proliferation. Journal of Clinical Investigation. 2025;135(19). doi:10.1172/jci187020

BibTeX
@article{Wortham2025,
  author = {Wortham, Matthew and Ramms, Bastian and Zeng, Chun and Benthuysen, Jacqueline R and Sai, Somesh and Pollow, Dennis P and Liu, Fenfen and Schlichting, Michael and Harrington, Austin R and Liu, Bradley and Prakash, Thazha P and Pirie, Elaine C and Zhu, Han and Baghdasarian, Siyouneh and Lee, Sean T and Ruthig, Victor A and Wells, Kristen L and Auwerx, Johan and Shirihai, Orian S and Sander, Maike},
  title = {The protein deacetylase SIRT2 exerts metabolic control over adaptive β cell proliferation},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {19},
  doi = {10.1172/jci187020}
}
Kostenlos starten →